iFAST Diagnostics
UK biotech developing rapid antimicrobial susceptibility testing with results in under three hours.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Caudal Energy, iFAST Diagnostics, Mykor — tidal energy, AMR testing and low-carbon biomaterials — Daily News May 27, 2026
Listen to the episodeAbout iFAST Diagnostics
iFAST Diagnostics develops a diagnostic platform to sharply reduce turnaround times for antimicrobial susceptibility testing. Its technology helps hospitals make faster treatment decisions and aims to curb the spread of antimicrobial resistance. The rapid antimicrobial susceptibility testing platform targets hospital laboratories and healthcare systems, competing with traditional AST workflows and other rapid diagnostics companies. The £5M round funds product development.
The Story
Founded in 2023; founder details were not verified in the reviewed sources.
How iFAST Diagnostics works
Business Model
B2B medtech/diagnostics model for hospital laboratories and healthcare systems.
Revenue Model
Not verified; likely device/test and consumables sales.
Products & Services
Key Products
- Rapid antimicrobial susceptibility testing platform
Core Use Cases
- AMR diagnostics
- Hospital infection testing
- Antibiotic therapy optimisation
Market & Clients
Key Customers
Hospital laboratories and healthcare systems.
Geographic Presence
How iFAST Diagnostics competes
Competitors
Competitive Advantages
- Results in under three hours
- UK rollout
- EU and FDA regulatory path
How iFAST Diagnostics grows
Growth Strategy
Expand UK rollout, secure EU approval and accelerate US FDA regulatory programme.
Distribution Model
B2B sales into hospitals and diagnostic laboratories.
Moat (Defensibility)
Clinical validation, regulatory progress and hospital workflow integration.
Regulatory Context
Requires medical diagnostics approvals across UK, EU and US markets.
Key Risks
- Regulatory delays
- Hospital procurement cycles
- Clinical adoption
- Competition from established diagnostics companies
Strategic Insights
- Rapid diagnostics are critical infrastructure against antimicrobial resistance.
- In medtech, value depends on clinical effectiveness, regulatory approval and hospital go-to-market.
- Non-dilutive funding can matter for healthtech startups with long regulatory pathways.
Funding & Investors
Total Funding
Funding Rounds
- 2026 - Funding round: £5M
Lead: Meridian Health Ventures
Key Investors
Founding Team
Key Executives
- Toby King - CEO
Key Metrics
Lessons from iFAST Diagnostics
- In healthcare markets, time saved can become measurable clinical value.
- Regulatory compliance must be designed into the scaling plan.
- Partnerships with hospitals and health systems are part of the product, not just distribution.
Similar Startups
BioOrbit
BioOrbit is a British startup that raised £9.8M seed in 2026 to manufacture cancer drugs in space. It develops an autonomous unit called BOX that uses microgravity to crystallize anti-cancer antibodies in purer form, potentially enabling subcutaneous administration formulations.
Read AnalysisWearable Robotics
Closed €5M Series A to expand exoskeletons and robotic devices for neuromotor rehabilitation—clinical and post-trauma recovery applications.
Read AnalysisBIOCOS IKE
A group of highly qualified professionals delivering innovative biotechnology solutions and expertise.
Read Analysis